DUF5 Protease Cleaving Ras Oncoproteins via Anthrax Toxin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to directly target and inhibit Ras proteins, which are frequently mutated in human cancers, making it challenging to treat Ras-dependent diseases.
Innovation Solution
Development of bacterial toxins, specifically the DUF5 protease, which cleaves Ras proteins, including mutant isoforms, to block cell proliferation by delivering the toxin to cancer cells using the anthrax lethal factor and protective antigen delivery system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional radiation or chemical therapy is used to treat cancer, then some therapeutic effect is achieved, but the therapy cannot specifically target Ras proteins and fails to effectively treat Ras-dependent cancers
Solution Approach 1:
The patent uses the anthrax toxin delivery system (protective antigen and lethal factor) as an intermediary to deliver the DUF5Vv protease specifically to cancer cells. The protective antigen binds to cell surface receptors and facilitates entry of the fused toxin-protease complex into the cytosol, where the protease then cleaves Ras proteins. This intermediary delivery mechanism enables specific targeting of Ras-dependent cancers that conventional therapies cannot address.
2Manufacturing precision
If DUF5Vv protease is delivered to cancer cells using the anthrax toxin delivery system, then specific cleavage of Ras proteins occurs, but the delivery system complexity increases
Solution Approach 1:
The patent merges the anthrax toxin delivery system with the DUF5Vv protease by creating a fusion protein between the lethal factor and the protease. This combined approach leverages the cell-targeting capability of the anthrax system while incorporating the Ras-cleaving function of DUF5Vv, achieving both specific delivery and specific molecular cleavage in a single therapeutic agent.
3Productivity
If Ras proteins are constitutively activated by mutations in cancer cells, then cell proliferation is driven, but conventional drugs cannot block this activated Ras
Solution Approach 1:
The patent takes out or removes the constitutively activated Ras proteins from cancer cells by using the DUF5Vv protease to cleave and degrade Ras at the Y32-D33 bond. This extraction approach directly eliminates the oncogenic driver (mutant Ras) rather than attempting to block its activity, thereby stopping the abnormal cell proliferation signal that conventional drugs fail to address.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The DUF5 protease effectively inhibits Ras activity, leading to cell cycle arrest and death in cancer cells, offering a novel therapeutic approach for Ras-dependent cancers by specifically targeting and irreversibly cleaving Ras proteins.
Implementation Method 1
DUF5Vv is an endopeptidase that cleaves Ras within Switch I
Implementation Method 2
delivering the toxin to cancer cells using the anthrax lethal factor and protective antigen delivery system
Data Source
AI summary
Disclosed are bacterial toxins and uses thereof as specific proteases for Ras sarcoma oncoproteins (Ras proteins). The bacterial toxins may be modified for use as pharmaceutical agents for treating Ras-dependent diseases and disorders including cell proliferation diseases and disorders such as cancer.